Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listOXYPHENYL BUTAZONE

OXYPHENYL BUTAZONE

Synonym(s):4-Butyl-1-(4-hydroxyphenyl)-2-phenyl-3,5-pyrazolidinedione;p-Hydroxyphenylbutazone;p-Oxyphenylbutazone;

  • CAS NO.:129-20-4
  • Empirical Formula: C19H20N2O3
  • Molecular Weight: 324.37
  • MDL number: MFCD00057278
  • EINECS: 204-936-2
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-13 21:11:14
OXYPHENYL BUTAZONE Structural

What is OXYPHENYL BUTAZONE?

Chemical properties

Light Beige Solid

Originator

Tanderil,Geigy,UK,1960

The Uses of OXYPHENYL BUTAZONE

Anti-inflammatory;Cyclooxygenase inhibito

Background

Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

What are the applications of Application

Oxyphenbutazone is a non-steroidal anti-inflammatory agent

Definition

ChEBI: A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following asso iation with blood dyscrasis and Stevens-Johnson syndrome.

Indications

Oxyphenbutazone (Oxalid, Tandearil) is the principal uricosuric metabolite of phenylbutazone. It has the same indications and toxicities as phenylbutazone.

Manufacturing Process

43.2 parts of n-butyl malonic acid ethyl ester are added to a solution of 4.6 parts of sodium in 92 parts by volume of absolute alcohol. 39 parts of pbenzyloxy hydrazobenzene (MP 88° to 90°C) are added. About two-thirds of the alcohol is distilled off and 92 parts by volume of absolute xylene are added. Without removing the sloping condenser, the mixture is stirred for 12 hours at a bath temperature of 140° to 145°C. It is then cooled to 0° to 5°C, 100 parts of ice are added, the xylene is removed, the aqueous solution is extracted twice with chloroform and made acid to Congo red at 0° to 5°C with 6 N hydrochloric acid.
The precipitate is taken up in chloroform, the solution obtained is washed twice with water, then with saturated salt solution, dried over Na2SO4and evaporated under vacuum (bath temperature 20°C). The residue is recrystallized from alcohol and produces 1-(p-benzyloxyphenyl)-2-phenyl-4-nbutyl-3,5-dioxo-pyrazolidine (C) as tiny white needles which melt at 132° to 133°C.
16.6 parts of (C) are suspended in 166 parts by volume of ethyl acetate and, in the presence of 16.6 parts of Raney nickel, hydrogen is allowed to act at room temperature and atmospheric pressure.
After 6 hours the calculated amount of hydrogen has been taken up. The residue obtained after filtering and evaporating is taken up in benzene and extracted twice with diluted sodium carbonate solution. The alkali extract is then made acid to Congo red with 6 N hydrochloric acid and the precipitate is taken up in ethyl acetate. The solution obtained is washed twice with salt solution, dried with sodium sulfate and evaporated. The residue is recrystallized from ether/petroleum ether. 1-(p-hydroxyphenyl)-2-phenyl-4-n Trade butyl-3,5-dioxo-pyrazolidine melts at 124° to 125°C.

brand name

Tandearil (Novartis);Algi-tandril;Anarreumol-b;Artzone;Buteril;Campozim;Defolgin;Difmedol;Dolo-phlogase;Dolo-tandril;Fibutrox;Gp 40705;Iltazon;Iltoxon;Inflamil;Mindaril;Miyadril;Oflamin;Otone;Oxybutazone;Oxybutol;Oxyperol;Oxyphenbutone;Phlogistol;Phlogont;Phloguran;Pilabutina;Realin;Rheumapax;Segudol;Suganril;Tanal;Tandacot;Teneral;Vefren.

Therapeutic Function

Antiinflammatory

World Health Organization (WHO)

Oxyphenbutazone, a pyrazolone derivative with anti-inflammatory, analgesic and antipyretic activity, was introduced in 1955 for the treatment of rheumatic disorders. It is one of the active metabolites of phenylbutazone and has a similar spectrum of activity including an association with serious and sometimes fatal adverse reactions, notably cases of aplastic anaemia and agranulocytosis. Many national drug regulatory authorities consider that more recently introduced drugs offer a safer alternative for most, if not all, patients requiring antiinflammatory agents. Although oxyphenbutazone has been widely withdrawn it remains available in some countries.

General Description

Oxyphenbutazone is a derivative compound of phenylbutazone. Oxyphenbutazone is one of the metabolites formed in the liver following administration of phenylbutazone. Given orally it causes fewer gastrointestinal adverse effects than phenylbutazone and is used at 300 – 400 mg/d for the same indications as the parent drug.

Biochem/physiol Actions

Oxyphenbutazone is a non-steroid anti inflammatory; anti Mycobacterium tuberculosis agent. Oxyphenbutazone is known to cause inflammatory effects on tissues. Oxyphenbutazone, as a drug, decreases cellular exudates, without involving the pituitary-adrenal axis or the immunity response. Though the drug delivers a number of side effects, it is considered to be less toxic than phenylbutazone, due to decreased rate of intestinal absorption.

Clinical Use

Oxyphenbutazone is a nonsteroidal anti-inflammatory drug, which was used by oral, rectal, or topical administration (400 - 600 mg/d) for the acute treatment of ankylosing spondylitis, chronic polyarthritis, and gout. Because of a high incidence of severe side effects including disturbances of the hematopoietic system like agranulocytosis and aplastic anemia the compound is no longer used. Oxyphenbutazone is a metabolite of phenylbutazone.

Metabolism

Not Available

Properties of OXYPHENYL BUTAZONE

Melting point: 109-111°C
Boiling point: 462.71°C (rough estimate)
Density  1.2118 (rough estimate)
refractive index  1.6140 (estimate)
storage temp.  -20°C
solubility  DMSO: soluble10mg/mL, clear
form  powder
pka pKa 4.7/10.0±0.2(H2O,t =25,Iundefined) (Uncertain)
color  white to brown
Water Solubility  20mg/L(room temperature)
Stability: Hygroscopic
CAS DataBase Reference 129-20-4(CAS DataBase Reference)
IARC 3 (Vol. 13, Sup 7) 1987
EPA Substance Registry System 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl- (129-20-4)

Safety information for OXYPHENYL BUTAZONE

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
ghs
Environment
GHS09
GHS Hazard Statements H302:Acute toxicity,oral
H400:Hazardous to the aquatic environment, acute hazard
Precautionary Statement Codes P273:Avoid release to the environment.

Computed Descriptors for OXYPHENYL BUTAZONE

Related products of tetrahydrofuran

You may like

  • Oxyphenbutazone CAS 129-20-4
    Oxyphenbutazone CAS 129-20-4
    129-20-4
    View Details
  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.